Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

Popular Searches

Looking for Something Else?

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (15)
Complete (2)

Showing 1-10 of 15

Sorted By:

A-Z
Z-A

Previous Next

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
AMG 757 20230298 Tarlatamab: A Phase 1b Study Evaluating Subcutaneous Tarlatamab in Subjects with Small Cell Lung Cancer
AMG 757 20240200: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Ph 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, & Efficacy of Tarlatamab in Combo w/AB248 in Pts w/Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
AZ D702BC00001 Artemide Lung 02: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
Assess efficacy and safety of rilvegostomig in combo with platinum-based chemo for the 1L treatment of patients with mNSCLC whose tumors express (PD-L1)
AZ D702FC00001 Artemide Lung 03: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
Evaluate efficacy and safety of rilvegostomig compared to pembro both in combo with platinum-based doublet chemo as a 1L treatment of patients with non-squam mNSCLC PD-L1
BGB-B455-101: A Phase 1, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B455 in Patients With Selected Advanced or Metastatic Solid Tumors
Ph 1 Open-Label Study Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Prelim Antitumor Activity of BGB-B455 in Pts w/Selected Adv/Met Solid Tumors
D7632C00001 TROPION-Lung10: A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy VersusPembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC = 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)
Dato-DXd in combo rilvego or rilvego mono compared pembro mono as a 1L in participants with locally NSCLC with PD-L1 expression and without actionable genomic alterations
D9078C00001 (PACIFIC-9): A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
Non-Small Cell Lung Cancer Phase III Durvalumab Oleclumab Monalizumab Placebo
J3M-MC-JZQH: A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
to assess if olomorasib durvalumab is more effective than durvalumab and placebo combination in unresectable KRAS G12C-mutant non-small cell lung cancer
MK2870-019_A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery (TroFuse-019)
Study to Assess Efficacy & Safety of Pembro With/Without Sacituzumab Tirumotecan (MK- 2870) in Adults With Resectable NSCLC Not Achieving pCR (MK-2870-019) (TroFuse-019)
MK6070-003: A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer
A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer

Previous Next